Axsome Therapeutics
AXSM
$204.07
-5.78%
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapies for central nervous system (CNS) disorders, with a marketed portfolio including Auvelity (AXS-05) for major depressive disorder and Sunosi for excessive daytime sleepiness, alongside a pipeline spanning AXS-07 for migraine, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Unlike clinical-stage peers, Axsome has crossed into commercial execution, generating meaningful product revenue while still investing heavily in label expansion and new indications, positioning it as a rare hybrid of growth-stage biotech and commercial-stage specialty pharma. The current investor narrative centers on the durability of Auvelity's launch trajectory — revenue grew 57.4% year-over-year to $191.2 million in Q1 2026 — and whether the company can reach profitability as operating leverage builds against a still-negative bottom line. Debate also swirls around pipeline catalysts, including AXS-07 and AXS-12 regulatory timelines, and whether the premium valuation (roughly 14x sales) is justified by the breadth of the CNS opportunity or leaves little room for execution missteps.…
AXSM
Axsome Therapeutics
$204.07
Related headlines
Investment Opinion: Should I buy AXSM Today?
The synthesized recommendation is a Buy, anchored by the strong analyst consensus (21 analysts, 'strong_buy' rating, average target $285.42 implying 29.3% upside) and the company's robust revenue growth trajectory. The core thesis is that Axsome is a rare commercial-stage biotech with a blockbuster-potential asset in Auvelity, a deep pipeline, and a clear path to profitability as operating leverage builds.
Supporting evidence includes: 1) Revenue growth of 57.4% YoY to $191.2 million in Q1 2026, with a trailing PS of 14.2x that, while premium, is justified by the growth rate; 2) Gross margin of 92.3%, which is best-in-class and provides significant operating leverage; 3) Improving free cash flow, which narrowed to -$20.8 million in Q1 2026 from -$43.7 million a year earlier; and 4) A strong balance sheet with $305.1 million in cash, sufficient to fund operations for several quarters. The forward PE of 43.9x, based on consensus EPS of $29.80, reflects expectations of a dramatic earnings inflection, but the PEG ratio of 1.29 suggests the valuation is reasonable relative to growth.
The biggest risks that could invalidate the thesis are: 1) A pipeline setback for AXS-07 or AXS-12, which would remove optionality and likely compress the multiple; 2) Slower-than-expected revenue growth or margin expansion, which would delay profitability and strain cash reserves; and 3) Competitive pressures in the CNS market. The rating would upgrade to a Strong Buy if the company demonstrates a clear path to positive net income within the next four quarters, or downgrade to Hold if revenue growth decelerates below 30% YoY or if cash burn accelerates. Relative to its history, the PS multiple of 14.2x is at its lowest level as a commercial-stage entity, suggesting the stock is undervalued compared to its own past, but it remains premium versus peers. Overall, the stock appears fairly valued with a bullish tilt, offering attractive risk/reward for growth-oriented investors.
Sign up to view all
AXSM 12-Month Price Forecast
Axsome presents a compelling growth story with a rare combination of high revenue growth, exceptional gross margins, and a deep pipeline. The valuation at 14.2x sales is premium but justified by the growth trajectory and the potential for a profitability inflection. The analyst community is overwhelmingly bullish, with no targets below $246, indicating strong conviction. However, the company remains unprofitable, and the premium multiple leaves little room for error. I would upgrade to high confidence if Axsome demonstrates positive net income or if pipeline catalysts materialize successfully; I would downgrade if revenue growth falls below 30% or if cash burn accelerates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axsome Therapeutics's 12-month outlook, with a consensus price target around $285.42 and implied upside of +39.9% versus the current price.
Average Target
$285.42
0 analysts
Implied Upside
+39.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$246 - $380
Analyst target range
Axsome is covered by 21 analysts, an unusually high number for a mid-cap biotech, reflecting strong institutional interest. The consensus recommendation is "strong_buy" with a recommendation mean of 1.24 (where 1.0 is a strong buy and 5.0 is a sell), indicating near-unanimous bullish sentiment. The average target price is $285.42, which implies approximately 29.3% upside from the current price of $220.75. This bullish consensus is reinforced by recent institutional ratings, which show a steady stream of Buy/Outperform reiterations from firms including HC Wainwright, RBC Capital, TD Cowen, Baird, Needham, Mizuho, and Wells Fargo throughout May–July 2026, with no downgrades or negative actions in the visible data.
The target price range spans from a low of $246.00 to a high of $380.00, a spread of $134 (roughly 55% of the average target), which signals meaningful disagreement about the company's trajectory. The high target of $380 implies roughly 72% upside and likely assumes successful pipeline readouts (AXS-07, AXS-12), continued Auvelity market share gains, and a clear path to profitability that justifies a premium multiple. The low target of $246 — still 11.4% above the current price — suggests that even the most conservative analyst sees upside, likely pricing in steady commercial execution but limited pipeline contribution or slower margin expansion. The tight clustering of targets above the current price (no analyst target below $246) is a strong signal of conviction, though the wide high-end spread indicates that the bull case depends heavily on binary pipeline catalysts. With estimated EPS averaging $29.80 (range $23.40–$34.92) and estimated revenue averaging $3.8 billion, the analyst community is modeling a dramatic multi-year transformation from a loss-making commercial-stage company to a highly profitable CNS leader.
Bulls vs Bears: AXSM Investment Factors
The bull case for Axsome rests on its exceptional revenue growth (57.4% YoY), industry-leading gross margins (92.3%), and a strong analyst consensus with 29.3% upside to the average target. The bear case highlights persistent net losses (-$64.5 million in Q1 2026), a premium valuation (14.2x sales), and high leverage (debt-to-equity of 2.73). Currently, the bull evidence appears stronger due to the company's commercial execution and improving cash flow trends, but the valuation leaves little margin for error. The single most important tension is whether Axsome can achieve profitability before cash reserves deplete or pipeline setbacks occur; a clear inflection to positive earnings would validate the premium multiple, while delays would likely trigger a sharp re-rating.
Bullish
- Revenue growth of 57.4% YoY: Q1 2026 revenue of $191.2 million grew 57.4% from $121.5 million in Q1 2025, driven by the commercial ramp of Auvelity and Sunosi. This growth rate is among the highest in specialty pharma and implies annualized revenue approaching $800 million, a critical scale threshold for profitability.
- Exceptional gross margin of 92.3%: Gross profit of $176.5 million on $191.2 million revenue yields a 92.3% gross margin, typical of branded CNS pharmaceuticals with minimal cost of goods. This high margin provides substantial operating leverage as revenue scales, with each incremental dollar of sales contributing heavily to future profitability.
- Strong analyst consensus with 29.3% upside: 21 analysts cover AXSM with a consensus rating of 'strong_buy' (mean 1.24) and an average target price of $285.42, implying 29.3% upside from the current $220.75. Notably, the lowest target of $246 is still 11.4% above the current price, indicating near-universal bullish sentiment.
- Improving cash burn and liquidity: Free cash flow improved to -$20.8 million in Q1 2026 from -$43.7 million in Q1 2025, while the company holds $305.1 million in cash. This suggests Axsome can fund operations for several more quarters without urgent external financing, reducing near-term solvency risk.
Bearish
- Persistent net losses and negative margins: Q1 2026 net loss was -$64.5 million on revenue of $191.2 million, a net margin of -33.8%. Despite improvement from -48.9% in Q1 2025, the company remains unprofitable, and operating expenses of $239.8 million continue to overwhelm gross profit.
- Premium valuation at 14.2x sales: AXSM trades at a trailing PS of 14.2x, a significant premium to the 4x-8x range typical for commercial-stage biotech peers. This valuation leaves little room for execution missteps and assumes flawless pipeline execution and a rapid path to profitability.
- High debt-to-equity ratio of 2.73: The debt-to-equity ratio of 2.73 indicates substantial leverage relative to a small equity base, which amplifies financial risk. With negative ROE of -207.5% and ROA of -16.3%, the company's capital structure is strained and could limit financial flexibility.
- Recent price momentum deceleration: While the stock is up 79.5% over the past year, it has declined 13.5% over the past three months and is down 16.5% relative to the S&P 500 in that period. This consolidation signals potential exhaustion of the prior rally and raises the risk of a deeper correction.
AXSM Technical Analysis
Axsome is in a sustained, powerful uptrend, with the stock up 79.5% over the past year and 23.5% year-to-date, massively outperforming the S&P 500's 16.2% and 12.1% gains over the same periods. At $220.75, the shares sit at roughly 74% of the 52-week range (low of $112.90, high of $260.19), meaning they are in the upper quartile but not at the highs — a positioning that suggests healthy momentum with room to run rather than an overextended blow-off top. The 52-week high of $260.19 remains about 18% above the current price, while the 52-week low of $112.90 is nearly 49% below, underscoring the wide trading band typical of a volatile biotech name.
Short-term momentum has been choppy and has decelerated relative to the longer-term trend: the stock is up just 2.8% over the past month and down 13.5% over the past three months, a sharp divergence from the 79.5% one-year gain. This 3-month pullback of 13.5% against a 1-year gain of 79.5% signals a meaningful consolidation phase, likely a digestion of the sharp April–June rally that took shares from roughly $158 in mid-March to a peak near $255 in mid-June. Notably, the stock has rebounded 4.6% in the latest session on volume of about 1.23 million shares, and the 1-month relative strength versus SPY is +3.9%, suggesting the recent pullback may be finding a floor. The 3-month relative strength of -16.5%, however, confirms the stock has lagged the market during this corrective phase, a classic mean-reversion pattern after a parabolic run.
Key technical support sits near the $198–$205 zone, which marked the August lows and roughly aligns with the 52-week low area of $112.90 as the ultimate downside floor, while resistance is defined by the 52-week high of $260.19 and the June peak near $255. A breakout above $260 would confirm trend resumption and likely open the door to new all-time highs, whereas a breakdown below $198 would signal a deeper correction toward the $180s. With a beta of just 0.706, Axsome is roughly 30% less volatile than the broader market on a statistical basis, which is unusual for a biotech and implies lower systematic risk — though the stock's max drawdown of -22.2% and wide 52-week range remind investors that idiosyncratic, catalyst-driven volatility remains substantial and position sizing should account for gap risk around clinical and regulatory events.
Beta
0.71
0.71x market volatility
Max Drawdown
-22.2%
Largest decline past year
52-Week Range
$113-$260
Price range past year
Annual Return
+74.8%
Cumulative gain past year
| Period | AXSM Return | S&P 500 |
|---|---|---|
| 1m | -4.5% | -2.4% |
| 3m | -19.1% | +2.2% |
| 6m | +28.4% | +14.8% |
| 1y | +74.8% | +14.6% |
| ytd | +14.2% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXSM Fundamental Analysis
Axsome's revenue trajectory is one of the strongest in specialty pharma, with Q1 2026 revenue of $191.2 million representing 57.4% year-over-year growth from $121.5 million in Q1 2025. The multi-quarter trend shows consistent sequential expansion — from $150.0 million in Q2 2025 to $171.0 million in Q3 2025 to $196.0 million in Q4 2025 — though the Q1 2026 figure of $191.2 million dipped slightly sequentially, likely reflecting seasonal prescription dynamics rather than demand deterioration. Product revenue dominates the mix at $189.4 million, with royalty revenue of $4.1 million and milestone revenue of $0.5 million, confirming that the commercial portfolio (Auvelity and Sunosi) is the growth engine. The 57.4% growth rate, while decelerating from prior periods as the base scales, still implies the company could approach $800 million–$1 billion in annualized revenue, a critical threshold for profitability.
Profitability remains elusive but is improving markedly: Q1 2026 net income was -$64.5 million on revenue of $191.2 million, a net margin of -33.8%, which is a substantial improvement from the -48.9% net margin in Q1 2025 and the -63.1% in Q4 2024. Gross margin is exceptionally high at 92.3% (gross profit of $176.5 million), typical of branded pharmaceuticals with minimal cost of goods, but operating expenses of $239.8 million — including $185.0 million in SG&A and $52.7 million in R&D — still overwhelm gross profit. The operating margin of -33.1% and EBITDA of -$61.1 million show that the company is burning cash to scale its commercial infrastructure, but the narrowing losses (EPS improved from -$1.22 in Q1 2025 to -$1.26 in Q1 2026 on a higher share count, with net loss actually shrinking from -$59.4 million to -$64.5 million) suggest the path to breakeven is visible if revenue growth continues.
On the balance sheet, Axsome carries $305.1 million in cash as of Q1 2026 against a debt-to-equity ratio of 2.73 and a current ratio of 1.55, indicating adequate but not fortress-like liquidity. Free cash flow remains negative at -$70.9 million on a trailing twelve-month basis, with Q1 2026 FCF of -$20.8 million, though this is a dramatic improvement from -$43.7 million in Q1 2025 and -$32.4 million in Q2 2025. The company has been funding operations partly through stock issuance ($16.2 million in Q1 2026, $43.8 million in Q2 2025), which dilutes shareholders but preserves cash. ROE of -207.5% and ROA of -16.3% reflect the still-negative earnings against a relatively small equity base, but the improving FCF trend and $305 million cash position suggest the company can fund itself internally for at least several more quarters without urgent external financing, reducing near-term solvency risk.
Quarterly Revenue
$191203000.0B
2026-03
Revenue YoY Growth
+57.4%
YoY Comparison
Gross Margin
92.3%
Latest Quarter
Free Cash Flow
$-70993000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXSM Overvalued?
Because Axsome's trailing net income is negative (EPS of -$0.02 on a trailing basis, with a trailing PE of -49.6x), the PE ratio is not meaningful, and the appropriate primary metric is the price-to-sales (PS) ratio. The stock trades at a trailing PS of 14.2x and an EV/Sales of 14.1x, while the forward PE of 43.9x — based on consensus EPS of $29.80 — implies the market expects a dramatic swing to profitability. The gap between the negative trailing PE and the positive forward PE of 43.9x signals that analysts are pricing in a near-term inflection to positive earnings, a high-conviction bet on operating leverage as revenue scales past the expense base.
Compared to the broader biotechnology sector, where price-to-sales multiples for commercial-stage companies typically range from 4x to 8x, Axsome's 14.2x PS represents a premium of roughly 75–250% depending on the peer set. This premium is justified in part by the company's 57.4% revenue growth rate, which far exceeds the mid-single-digit to low-double-digit growth of most established biopharma peers, and by its 92.3% gross margin, which is best-in-class. However, the premium also reflects pipeline optionality (AXS-07, AXS-12, AXS-14) that is not yet generating revenue, meaning any clinical or regulatory setback would likely compress the multiple sharply. The EV/EBITDA of -53.6x is negative and thus not comparable, but the forward PE of 43.9x versus a sector average forward PE of roughly 15–18x for large-cap pharma highlights how much growth is already priced in.
Historically, Axsome's PS ratio has been extremely volatile, ranging from a low of 28.4x in Q1 2023 to a high of 169.7x in Q2 2022, with the current 14.2x representing the lowest level in the company's history as a commercial-stage entity. This compression reflects the rapid revenue growth catching up to the valuation — the denominator (sales) has grown faster than the numerator (market cap). The current PS of 14.2x is well below the 34.6x–47.2x range seen throughout 2025, suggesting that either the market has repriced the stock to a more sustainable multiple or that investors are awaiting proof of profitability before awarding a higher multiple. If the company hits consensus revenue of $3.8 billion (which appears to be a multi-year estimate given the current run-rate of ~$765 million annualized), the valuation would look far more reasonable, but near-term the stock is priced for flawless execution.
PE
-49.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, primarily stemming from Axsome's unprofitable operations and high leverage. The company reported a net loss of -$64.5 million in Q1 2026, with a net margin of -33.8%, and free cash flow remains negative at -$70.9 million on a trailing twelve-month basis. Although cash reserves of $305.1 million provide a cushion, the debt-to-equity ratio of 2.73 and current ratio of 1.55 indicate that liabilities are substantial relative to equity, and continued losses could strain liquidity if revenue growth decelerates. Additionally, revenue is concentrated in Auvelity and Sunosi, making the company vulnerable to competitive pressures or reimbursement challenges in the CNS market.
Market and competitive risks include the potential for valuation compression given the premium PS multiple of 14.2x, which is well above the 4x-8x range for commercial-stage biotech peers. The stock's beta of 0.706 suggests lower systematic risk, but idiosyncratic volatility remains high, as evidenced by a max drawdown of -22.2% and a wide 52-week range ($112.90 to $260.19). Competitive threats in the depression and CNS space are intensifying, and any negative regulatory news or clinical trial failures for pipeline candidates like AXS-07 or AXS-12 could trigger a sharp sell-off. Furthermore, the recent 13.5% three-month decline and -16.5% relative underperformance versus the S&P 500 highlight the risk of sector rotation away from high-multiple biotech.
The worst-case scenario would involve a combination of pipeline failure, slowing revenue growth, and a broader market downturn. If Axsome's pipeline candidates fail to gain approval or if Auvelity's growth stalls, the stock could retest its 52-week low of $112.90, representing a decline of approximately 49% from the current price of $220.75. Even the analyst low target of $246 is above the current price, but in a severe bear case, the stock could fall to the 52-week low, implying a loss of nearly half of invested capital. Investors should be prepared for significant drawdowns, as the stock has already experienced a max drawdown of -22.2% from its peak.
FAQ
The key risks for AXSM are ranked as follows: 1) Financial risk: The company is unprofitable with a net loss of -$64.5 million in Q1 2026 and negative free cash flow of -$70.9 million TTM, which could lead to dilutive financing if cash reserves deplete. 2) Pipeline risk: The bull case depends on successful development of AXS-07, AXS-12, and AXS-14; any clinical or regulatory setback could significantly reduce the valuation. 3) Competitive risk: The CNS market is highly competitive, and Auvelity faces competition from other antidepressants, which could pressure pricing and market share. 4) Macro risk: As a high-multiple biotech, AXSM is sensitive to interest rate changes and sector rotation, as evidenced by its 13.5% three-month decline despite a 79.5% one-year gain. Each risk is substantial, but the financial and pipeline risks are the most severe.
The 12-month forecast for AXSM includes three scenarios: a bull case with 30% probability targeting $285-$380, a base case with 50% probability targeting $246-$285, and a bear case with 20% probability targeting $112.90-$246. The base case is most likely, assuming revenue growth of 45% YoY to approximately $1.1 billion annualized, gross margins above 90%, and free cash flow turning positive by Q4 2026. The key assumption behind the base case is steady commercial execution without major pipeline setbacks. The bull case hinges on successful pipeline approvals and an earlier profitability inflection, while the bear case assumes revenue deceleration and pipeline delays. The analyst average target of $285.42 aligns with the base case, implying 29.3% upside.
AXSM appears fairly valued with a bullish tilt, trading at a trailing PS of 14.2x, which is a premium to the 4x-8x range for commercial-stage biotech peers. However, this premium is supported by the company's 57.4% revenue growth and 92.3% gross margin, which are well above sector averages. The forward PE of 43.9x, based on consensus EPS of $29.80, implies the market expects a dramatic earnings inflection, and the PEG ratio of 1.29 suggests the valuation is reasonable relative to growth. Compared to its own history, the current PS of 14.2x is the lowest since becoming commercial-stage, indicating that the stock is undervalued relative to its past multiples. The market is pricing in flawless execution and successful pipeline development, leaving little room for error.
From a risk/reward perspective, AXSM offers a favorable setup for growth-oriented investors. The stock trades at $220.75, with a consensus analyst target of $285.42, implying 29.3% upside, and the lowest target of $246 still suggests 11.4% upside. The company's revenue grew 57.4% YoY in Q1 2026, and gross margins are exceptionally high at 92.3%, providing a strong foundation for future profitability. However, the biggest downside risk is the premium valuation at 14.2x sales, which could compress if growth slows or pipeline setbacks occur. For investors comfortable with volatility and a multi-year horizon, AXSM is a good buy, but position sizing should account for the potential of a 49% drawdown to the 52-week low of $112.90 in a worst-case scenario.
AXSM is more suitable for long-term investment due to its growth stage, volatile earnings, and binary pipeline catalysts. The company does not pay a dividend, and its beta of 0.706 suggests lower market correlation, but idiosyncratic volatility is high, with a max drawdown of -22.2% and a wide 52-week range. Earnings visibility is limited as the company is not yet profitable, and quarterly results can swing on prescription trends and expenses. Short-term trading would require timing around binary events like FDA decisions, which is highly risky. A suggested minimum holding period is 2-3 years to allow for pipeline maturation and the realization of profitability, which would likely drive the stock toward the analyst targets.